Technical Analysis for NCNA - NuCana plc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
24.5 | 4.17% | 0.98 |
NCNA closed up 4.17 percent on Friday, June 22, 2018, on 24 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | N/A | Down | Down |
| See historical NCNA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jun 22 | Bullish Engulfing | Bullish | 0.00% |
| Jun 22 | NR7 | Range Contraction | 0.00% |
| Jun 22 | Lower Bollinger Band Walk | Weakness | 0.00% |
| Jun 22 | Lower Bollinger Band Touch | Weakness | 0.00% |
| Jun 22 | Oversold Stochastic | Weakness | 0.00% |
| Jun 21 | MACD Bearish Centerline Cross | Bearish | 4.17% |
| Jun 21 | New Downtrend | Bearish | 4.17% |
| Jun 21 | Lower Bollinger Band Walk | Weakness | 4.17% |
| Jun 21 | Below Lower BB | Weakness | 4.17% |
| Jun 21 | Down 3 Days in a Row | Weakness | 4.17% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Pharmaceuticals
NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more NCNA news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 32.0 |
| 52 Week Low | 9.32 |
| Average Volume | 51,879 |
| 200-Day Moving Average | 0.0 |
| 50-Day Moving Average | 25.0071 |
| 20-Day Moving Average | 26.7708 |
| 10-Day Moving Average | 25.7025 |
| Average True Range | 1.9783 |
| ADX | 30.49 |
| +DI | 16.93 |
| -DI | 17.65 |
| Chandelier Exit (Long, 3 ATRs ) | 26.0651 |
| Chandelier Exit (Short, 3 ATRs ) | 28.9349 |
| Upper Bollinger Band | 30.33 |
| Lower Bollinger Band | 23.2116 |
| Percent B (%b) | 0.18 |
| BandWidth | 26.590165 |
| MACD Line | -0.2739 |
| MACD Signal Line | 0.3377 |
| MACD Histogram | -0.6116 |
| Fundamentals | Value |
|---|---|
| Market Cap | 779.37 Million |
| Num Shares | 31.8 Million |
| EPS | -0.40 |
| Price-to-Earnings (P/E) Ratio | -61.25 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 0.00 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 26.75 | ||||
| Resistance 3 (R3) | 26.50 | 25.50 | 26.38 | ||
| Resistance 2 (R2) | 25.50 | 24.93 | 25.63 | 26.25 | |
| Resistance 1 (R1) | 25.00 | 24.57 | 25.25 | 25.25 | 26.12 |
| Pivot Point | 24.00 | 24.00 | 24.13 | 24.13 | 24.00 |
| Support 1 (S1) | 23.50 | 23.43 | 23.75 | 23.75 | 22.88 |
| Support 2 (S2) | 22.50 | 23.07 | 22.63 | 22.75 | |
| Support 3 (S3) | 22.00 | 22.50 | 22.63 | ||
| Support 4 (S4) | 22.25 |
